Stay tuned for MiNK’s upcoming presentation at #AACR24. On April 8, MiNK will present preclinical data on MiNK-215, our IL-15 armored FAP-targeting CAR-iNKT cell therapy, demonstrating its unique potential against liver metastases in MSS CRC. Learn more: bit.ly/4c5Y8yQ

Today at AACR we demonstrated the power of MiNK's iNKTs to overcome the limitations of immune checkpoint blockade therapy to eliminate MSS colorectal liver metastases. Potential to be a powerful combination partner with Bot/BAL. #AACR24, #Immunotherapy. MiNK Therapeutics Agenus.

New dual TIGIT & CD96 blocking immunotherapy drug effective in activating anti-cancer immune response in mouse models. Efficacy increased when combined with PD-L1 blocking immunotx. Phase 1/2 trial that includes patients w/ #NSCLC ongoing #AACR24

Ecstatic and proud to share the NICHE-2 results, now published in NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. John Haanen nej.md/3Ku4X0H

Just published in Nature Medicine. Botensilimab, a multifunctional Fc-enhanced anti-CTLA-4 antibody is transforming the treatment landscape for patients with MSS colorectal cancer. #CancerResearch #CRC #Immunotherapy nature.com/articles/s4159…

2 new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated & elicited encouraging clinical responses in patients with relapsed/refractory microsatellite stable #ColorectalCancer Anthony El-Khoueiry Dana-Farber MD Anderson Cancer Center City of Hope nature.com/articles/s4159…

🔥🔥🔥congrats Agenus breaking through the most frequent and aggressive #MSSCRC cancers. Pathbreaking Pashtoon Kasi MD, MS #BOT

📢 NCI Announces Availability of Botensilimab for Clinical Development Botensilimab is available through the NCI CTEP program in collaboration with Agenus. Strong LOIs for clinical studies are being evaluated. investor.agenusbio.com/news/news-deta…

Also, this new class of next-gen CTLA4 drugs has multiple potential beneficial effects beyond simple Treg depletion. Beautiful recent data from Agenus Dhan Chand supports many of our findings on this front! aacrjournals.org/cancerdiscover… (15/17)

Excited to share our latest research at #SITC2024! Priya Iyer presents AGEN1721: a novel Fc-enhanced bifunctional antibody targeting FAP & TGFβ. Depletes FAP+ CAFs & neutralizes TGFβ to transform immune-excluded tumors. Visit Poster #1355 today! #immunotherapy #cancer"

Excited to be presenting at the #GlobalCancerMovement conference today! Join me to discuss our groundbreaking work on Botensilimab in treating immunologically 'cold' and treatment-refractory #colorectal #cancer #Immunotherapy Agenus Sign up oncodaily.com/movement/gcm-c…

📢Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers Botensilimab is poised to revolutionize the treatment of MSS colorectal cancer, offering promising results and a new hope for patients with limited options. Dhan Chand Agenus

From the December issue: Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy bit.ly/4gqFUKh By Dhan Chand and colleagues Agenus

ASCO #GI25 The future of immunotherapy in MSS colon cancer is here! UNICORN trial results Preoperative botensilimab (BOT) w or w/o balstilimab (BAL) for patients w/ resectable locally advanced pMMR or dMMR colon cancer: NCT05845450 PI: Filippo Pietrantonio meetings.asco.org/abstracts-pres…

🆕#GI25 abstracts now released! 📰 🗞️ Neoadjuvant #immunotherapy continues to impress! Building upon the paradigm shift of immunotherapy to earlier settings ➡️📈CURES🙌🏽 ✅NEST🪺 ✅UNICORN🦄 ✅NICHE These trials📚~80 treated. ✔️SAFE. 🔜Time for a phase-2/3. OncoAlert #CRCSM

GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the pts had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT

What a shift! In 2021, I was among people who loved reading CancerWorld , now I authored the COVER story! 🤩 Huge honor and Motivation to Dream Big! Discussing Role Of IOs - BOT + BAL & the impact beyond data in MSS colon cancer. Check it out ⬇️ cancerworld.net/botensilimab-a…

When the “coldest” tumors melt: Myriam Chalabi breaks new ground (again) at #AACR25. NEOASIS Trial: • 80% MPR in dMMR (70% pCR!) • 60% MPR in pMMR BOT/BAL are pushing ICB into non-immunogenic tumors. #CancerImmunotherapy #BOT/BAL

Nothing against radiation☢️but if we can have #immunotherapy like BOT/BAL eradicate/cure cancer, we can set a similar paradigm for our patients with MSS🔵 #ColorectalCancer as is now the case for patients with MSI-High🔴 tumors and spare additional toxicity. Now City of Hope 👇🏽🙌🏽

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in Nature Cancer MarleenKokLab doi.org/10.1038/s43018…